2012
Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
Abstract: BackgroundDuring the 2009-2010 pandemic in Norway, 12 513 laboratory-confirmed cases of pandemic influenza A(H1N1)pdm09, were reported to the Norwegian Surveillance System for Communicable Diseases (MSIS). 2.2 million persons (45% of the population) were vaccinated with an AS03-adjuvanted monovalent vaccine during the pandemic. Most of them were registered in the Norwegian Immunisation Registry (SYSVAK). Based on these registries, we aimed at estimating the vaccine effectiveness (VE) and describing vaccine fai…
Search citation statements
Paper Sections
Select...
9
3
1
1
Citation Types
1
4
0
1
Year Published
2012
2026
Publication Types
Select...
12
1
Relationship
1
12
Authors
Journals
Cited by 12 publications
(6 citation statements)
References 9 publications
1
4
0
1
“…However, the cohort was population‐based and most women reported moderate illness. Thus, few of the pregnant women were subjected to laboratory testing . This is also in line with a national registry study indicating that most Norwegian pandemic cases during pregnancy were mild to moderate, and among 46 000 pregnant women, only 40 were hospitalized with influenza during the pandemic wave and only 516 cases of laboratory‐confirmed influenza were registered .…”
Section: Discussionsupporting
confidence: 69%
“…However, the cohort was population‐based and most women reported moderate illness. Thus, few of the pregnant women were subjected to laboratory testing . This is also in line with a national registry study indicating that most Norwegian pandemic cases during pregnancy were mild to moderate, and among 46 000 pregnant women, only 40 were hospitalized with influenza during the pandemic wave and only 516 cases of laboratory‐confirmed influenza were registered .…”
Section: Discussionsupporting
confidence: 69%
“…The main limitation of our study is the possible misclassification of the exposures. Due to limited capacity during the pandemic, laboratory testing of suspected A(H1N1)pdm09 influenza cases was restricted [ 21 ]. Less than 1/5 of the cases in our study, and only about 1/3 of the medically attended cases, were laboratory confirmed.…”
Section: Discussionmentioning
confidence: 99%
“…In Norway, the main wave of the pandemic occurred from October 1, 2009 to December 31, 2009 [ 15 ]. A vaccination campaign against A(H1N1)pdm09 was started in mid-October 2009 [ 21 ]. The vaccine was recommended to all pregnant women in the second or third trimester.…”
Section: Methodsmentioning
confidence: 99%
“…In Sweden, the estimated (weekly) VE was 69–89% during the maximum influenza activity in adults 30–64 years of age, and even higher in children [17] . In Norway, the weekly VE during the epidemic ranged from 77% to 96% in a population-based retrospective cohort study combining the disease surveillance and vaccination registers [37] . High VE (>90%) has also been shown for mainly AS03-adjuvanted pandemic vaccine in Germany among 14–59-year-old individuals and among Portuguese healthcare workers [15] , [18] .…”
Section: Discussionmentioning
confidence: 99%
